131 related articles for article (PubMed ID: 36336127)
1. Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia.
Lipreri da Silva JC; Saldanha-Araujo F; de Melo RCB; Vicari HP; Silva-Carvalho AE; Rego EM; Buccheri V; Machado-Neto JA
Life Sci; 2022 Dec; 311(Pt B):121146. PubMed ID: 36336127
[TBL] [Abstract][Full Text] [Related]
2. NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells.
Lipreri da Silva JC; Carvalho MFL; de Miranda LBL; de Almeida BO; Lima K; Machado-Neto JA
Invest New Drugs; 2022 Aug; 40(4):728-737. PubMed ID: 35477813
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.
Lipreri da Silva JC; Coelho-Silva JL; Lima K; Vicari HP; Lazarini M; Costa-Lotufo LV; Traina F; Machado-Neto JA
Cell Oncol (Dordr); 2021 Oct; 44(5):1105-1117. PubMed ID: 34196912
[TBL] [Abstract][Full Text] [Related]
4. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
6. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
[TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
8. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
9. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
10. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
12. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
13. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
14. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
16. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
[TBL] [Abstract][Full Text] [Related]
17. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
[TBL] [Abstract][Full Text] [Related]
18. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
[TBL] [Abstract][Full Text] [Related]
19. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
20. DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.
Szoltysek K; Ciardullo C; Zhou P; Walaszczyk A; Willmore E; Rand V; Marshall S; Hall A; J Harrison C; Eswaran J; Soundararajan M
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]